MAP2K4 and neoplasm: Since metastasis suppressors are able to trigger tumor dormancy, the metastasis suppressor role of METCAM/MUC18 in the malignant propensity of human ovarian carcinoma cell lines may be useful for designing novel therapeutic methods to treat clinical ovarian carcinomas, similar to the clinical application of other metastasis suppressors, such as KISS1, KAI1, nm23, MAP2K4 and some micro-RNAs to arrest other cancers [44].